drugset

Drugs / Standard-dose rtPA

Follow last change Aug 2018 re-read 3 minutes ago

Standard-dose rtPA

Protein / enzyme biologic

Developed for: ischemic stroke
Investigated by: Conselho Nacional de Desenvolvimento Científico e Tecnológico · National Health and Medical Research Council, Australia · Takeda · The George Institute · The Stroke Association, United Kingdom

Trials 1

today NCT01422616 · Ph 3

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01422616	Mar 2012 → Aug 2018	hypertensive disorder, ischemic stroke	The George Institute	Completed	Missed primary

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Standard-dose rtPA	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01422616 ↗
Modality	Protein / enzyme biologic	“recombinant tissue plasminogen activator (rtPA)” NCT01422616 ↗